Cutaneous Lymphoma and Antibody-Directed Therapies
The introduction of monoclonal antibodies such as rituximab to the treatment of cancer has greatly advanced the treatment scenario in onco-hematology. However, the response to these agents may be limited by insufficient efficacy or resistance. Antibody–drug conjugates are an attractive strategy to d...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-03-01
|
| Series: | Antibodies |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4468/12/1/21 |
| _version_ | 1797613836265586688 |
|---|---|
| author | Alvise Sernicola Christian Ciolfi Paola Miceli Mauro Alaibac |
| author_facet | Alvise Sernicola Christian Ciolfi Paola Miceli Mauro Alaibac |
| author_sort | Alvise Sernicola |
| collection | DOAJ |
| description | The introduction of monoclonal antibodies such as rituximab to the treatment of cancer has greatly advanced the treatment scenario in onco-hematology. However, the response to these agents may be limited by insufficient efficacy or resistance. Antibody–drug conjugates are an attractive strategy to deliver payloads of toxicity or radiation with high selectivity toward malignant targets and limited unwanted effects. Primary cutaneous lymphomas are a heterogeneous group of disorders and a current area of unmet need in dermato-oncology due to the limited options available for advanced cases. This review briefly summarizes our current understanding of T and B cell lymphomagenesis, with a focus on recognized molecular alterations that may provide investigative therapeutic targets. The authors reviewed antibody-directed therapies investigated in the setting of lymphoma: this term includes a broad spectrum of approaches, from antibody–drug conjugates such as brentuximab vedotin, to bi-specific antibodies, antibody combinations, antibody-conjugated nanotherapeutics, radioimmunotherapy and, finally, photoimmunotherapy with specific antibody–photoadsorber conjugates, as an attractive strategy in development for the future management of cutaneous lymphoma. |
| first_indexed | 2024-03-11T07:00:19Z |
| format | Article |
| id | doaj.art-2be7039f79294d74abad858335327d37 |
| institution | Directory Open Access Journal |
| issn | 2073-4468 |
| language | English |
| last_indexed | 2024-03-11T07:00:19Z |
| publishDate | 2023-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antibodies |
| spelling | doaj.art-2be7039f79294d74abad858335327d372023-11-17T09:16:06ZengMDPI AGAntibodies2073-44682023-03-011212110.3390/antib12010021Cutaneous Lymphoma and Antibody-Directed TherapiesAlvise Sernicola0Christian Ciolfi1Paola Miceli2Mauro Alaibac3Dermatology Unit, Department of Medicine (DIMED), University of Padua, 35121 Padova, ItalyDermatology Unit, Department of Medicine (DIMED), University of Padua, 35121 Padova, ItalyDermatology Unit, Department of Medicine (DIMED), University of Padua, 35121 Padova, ItalyDermatology Unit, Department of Medicine (DIMED), University of Padua, 35121 Padova, ItalyThe introduction of monoclonal antibodies such as rituximab to the treatment of cancer has greatly advanced the treatment scenario in onco-hematology. However, the response to these agents may be limited by insufficient efficacy or resistance. Antibody–drug conjugates are an attractive strategy to deliver payloads of toxicity or radiation with high selectivity toward malignant targets and limited unwanted effects. Primary cutaneous lymphomas are a heterogeneous group of disorders and a current area of unmet need in dermato-oncology due to the limited options available for advanced cases. This review briefly summarizes our current understanding of T and B cell lymphomagenesis, with a focus on recognized molecular alterations that may provide investigative therapeutic targets. The authors reviewed antibody-directed therapies investigated in the setting of lymphoma: this term includes a broad spectrum of approaches, from antibody–drug conjugates such as brentuximab vedotin, to bi-specific antibodies, antibody combinations, antibody-conjugated nanotherapeutics, radioimmunotherapy and, finally, photoimmunotherapy with specific antibody–photoadsorber conjugates, as an attractive strategy in development for the future management of cutaneous lymphoma.https://www.mdpi.com/2073-4468/12/1/21cutaneous lymphomamonoclonal antibodiesrituximabbrentuximab vedotinphotoimmunotherapyantibody–drug conjugates |
| spellingShingle | Alvise Sernicola Christian Ciolfi Paola Miceli Mauro Alaibac Cutaneous Lymphoma and Antibody-Directed Therapies Antibodies cutaneous lymphoma monoclonal antibodies rituximab brentuximab vedotin photoimmunotherapy antibody–drug conjugates |
| title | Cutaneous Lymphoma and Antibody-Directed Therapies |
| title_full | Cutaneous Lymphoma and Antibody-Directed Therapies |
| title_fullStr | Cutaneous Lymphoma and Antibody-Directed Therapies |
| title_full_unstemmed | Cutaneous Lymphoma and Antibody-Directed Therapies |
| title_short | Cutaneous Lymphoma and Antibody-Directed Therapies |
| title_sort | cutaneous lymphoma and antibody directed therapies |
| topic | cutaneous lymphoma monoclonal antibodies rituximab brentuximab vedotin photoimmunotherapy antibody–drug conjugates |
| url | https://www.mdpi.com/2073-4468/12/1/21 |
| work_keys_str_mv | AT alvisesernicola cutaneouslymphomaandantibodydirectedtherapies AT christianciolfi cutaneouslymphomaandantibodydirectedtherapies AT paolamiceli cutaneouslymphomaandantibodydirectedtherapies AT mauroalaibac cutaneouslymphomaandantibodydirectedtherapies |